Collectively, our findings provide the evidence that lncCSMD1 promotes hepatocarcinogenesis by stabilizing MYC protein and may be considered as a new potential biomarker for prognostic prediction and target for HCC therapy in the future. The gene discussed is MYC; the disease is hepatocellular carcinoma.